Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Investment Securities: 2014-2025

Historic Gains from Investment Securities for Aytu Biopharma (AYTU) over the last 12 years, with Jun 2025 value amounting to $211,618.

  • Aytu Biopharma's Gains from Investment Securities rose 46.21% to $206,800 in Q3 2025 from the same period last year, while for Sep 2025 it was $206,800, marking a year-over-year increase of 46.21%. This contributed to the annual value of $211,618 for FY2025, which is 44.41% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Gains from Investment Securities is $211,618, which was up 44.41% from $146,539 recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Gains from Investment Securities registered a high of $211,618 during FY2025, and its lowest value of $3,899 during FY2022.
  • Its 3-year average for Gains from Investment Securities is $136,973, with a median of $146,539 in 2024.
  • Per our database at Business Quant, Aytu Biopharma's Gains from Investment Securities crashed by 96.44% in 2022 and then skyrocketed by 1,253.22% in 2023.
  • Aytu Biopharma's Gains from Investment Securities (Yearly) stood at $109,588 in 2021, then slumped by 96.44% to $3,899 in 2022, then surged by 1,253.22% to $52,762 in 2023, then spiked by 177.74% to $146,539 in 2024, then skyrocketed by 44.41% to $211,618 in 2025.